Effect of Clarithromycin on the Pharmacokinetics of Cabergoline in Healthy Controls and in Patients With Parkinson’s Disease

Effect of Clarithromycin on the Pharmacokinetics of Cabergoline in Healthy Controls and in Patients With Parkinson’s Disease

Abstract.: Cabergoline is used in the treatment of Parkinson’s disease (PD). Clarithromycin is a potent inhibitor of CYP3A4 and P-glycoprotein and is often co-administered with cabergoline in usual clinical practice. We studied the effect of clarithromycin co-administration on the blood concentratio...

Full description

Bibliographic Details
Main Authors: Akiko Nakatsuka, Masahiro Nagai, Hayato Yabe, Noriko Nishikawa, Takuo Nomura, Hiroyoko Moritoyo, Takashi Moritoyo, Masahiro Nomoto
Format: Article
Language:English
Published: Elsevier 2006-01-01
Series:Journal of Pharmacological Sciences
Online Access:http://www.sciencedirect.com/science/article/pii/S1347861319345396

Similar Items

Similar Items